A Randomized Multicenter Trial Comparing the Efficacy of Simvastatin and Fluvastatin

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 1, Issue 1, 1996, Pages 23-29

  Illingworth, D R ^a   Stein, E A ^b   Knopp, R H ^c   Hunninghake, D B ^d   Davidson, M H ^e   Dujovne, C A ^f   Miller, V T ^g   Tobert, J A ^h   Laskarzewski, P M ^b   Isaacsohn, J L ⁱ   Bacon, S P ^a   Tate, A C ^h  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b Pharmaceutical Product Development   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d Experimental Surgical Services   (United States)

^e RADIANT RESEARCH   (United States)

^f UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^g GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^h MERCK RESEARCH LABORATORIES   (United States)

ⁱ CHRIST HOSPITAL   (United States)

Author keywords

fluvastatin; hypercholes terolemia; inhibitors of HMG CoA reductase; simvastatin

Indexed keywords

EID: 84992791486     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/107424849600100105     Document Type: Article

References (27)

1. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383, 1994
2. Maas investigators. Effect of simvastatin on coronary atheroma: The Multicentre Anti-Atheroma Study (MAAS). Lancet 344: 633, 1994
3. Blankenhorn DH, Azen SP, Kramsch DM, et al. The Monitored Atherosclerosis Regression Study (MARS): Coronary angiographic changes with lovastatin therapy. Ann Intern Med 119: 969, 1993
4. Waters D., Higginson L., Gladstone P., et al. Effects of monotherapy with an HMG CoA Reductase Inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: The Canadian Coronary Atherosclerosis Intervention Trial (CCAIT). Circulation 89: 959, 1994
5. Levy RI, Troendle AJ, Fattu JM A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin. Circulation 87(suppl III):45, 1993
6. Peters TK, Mehra M. Muratti EN Efficacy and safety of fluvastatin in hypertensive patients: An analysis of a clinical trial database. Am J Hypertens (suppl III):2, 1993
7. Illingworth DR, Erkelens DW, Keller U., Thompson G., Tikkanen MJ Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin. Lancet 343: 1554, 1994
8. Illingworth DR, Tobert JA A review of clinical trials comparing HMG-CoA reductase inhibitors. Clin Therapeut 16: 366, 1994
9. Conti CR Economics of lipid lowering with HMG-CoA reductase inhibitors. Clin Cardiol 18: 60, 1995 (editorial)
10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation 89: 1329, 1994
11. Hunninghake DB, Miller VT, Palmer RH, et al. Therapeutic response to lovastatin (mevinolin) in non-familial hypercholesterolemia: A multicenter study. JAMA 256: 2829, 1986
12. Havel RJ, Hunninghake DB, Illingworth DR, et al. Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia: A multicenter study. Ann Intern Med 107: 609, 1987
13. Steiner PM, Freidel J., Bremner WF, Stein EA Standardization of micromethods for plasma cholesterol, triglyceride and HDL-cholesterol with the lipid clinics’ methodology (abstr). J Clin Chem 19: 850, 1981
14. Myers GL, Cooper GR, Winn CL, Smith SJ The Centers for Disease Control-National Heart, Lung, and Blood Institute Lipid Standardization Program: An approach to accurate and precise lipid measurements. Clin Lab Med 9: 105, 1989
15. Warnick GR, Albers JJ A comprehensive evaluation of the heparin manganese precipitation procedure for estimating high-density lipoprotein cholesterol. J Lipid Res 19: 65, 1978
16. Friedewald WT, Levy RI, Frederickson DS Estimation of the concentration of low-density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499, 1972
17. Searle SR Linear models. New York, John Wiley, 1971
18. Zerbe GO On Fieller's theorem and the general linear model. Amer Statistic 32: 103, 1978
19. Zeger SL, Liang K. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 42: 121, 1986
20. Bradford RH, Shear CL, Chremos AN, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results. Arch Intern Med 151: 43, 1991
21. Davidson MH, on behalf of the FLUENT Investigators Group. Fluvastatin long-term extension trial (FLUENT): Summary of efficacy and safety. Am J Med 96(suppl 6A): 41S, 1994
22. Ose L., Scott R., and the Simvastatin-Fluvastatin Study Group. Efficacy of simvastatin vs. fluvastatin in patients with primary hypercholesterolemia. Clin Drug Invest 10: 127, 1995
23. Berger ML, Wilson HM, Liss CL A comparison of the safety and efficacy of lovastatin and fluvastatin. Abstract of the 64th Congress of the European Atherosclerosis Society, Utrecht, the Netherlands, June 10-13, 1995
24. Larsen ML, Illingworth DR Drug treatment of dyslipoproteinemia. Med Clin North Am 78: 225, 1994
25. Law MR, Wald NJ, Thompson SG By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 308: 367, 1994
26. Gould AL, Rossouw JE, Santanello NC, Heyse J., Furberg CD Cholesterol reduction yields clinical benefit: A new look at old data. Circulation 91: 2274, 1995
27. Resource Utilization for Acute Cardiovascular Events: Results from the Scandinavian Simvastatin Survival Study (4S). Pedersen TR and Kjekshus J, on behalf of the Scandinavian Simvastatin Survival Study Group. Eur Heart J 16(Abstract Supplement August):158, 1995